Skip to content
‹ Back to IndustriesHealthcare

A Pulmonary Expert Weighs in on the Johnson & Johnson COVID-19 Vaccine’s Pause

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.   On this episode,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Dr. José Medina-Inojosa · ·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.

On this episode, hosts Dr. Jose Medina-Inojosa and Alisa Johnsrud talked with Jonathan Baktari, MD, about the Johnson and Johnson vaccine pause due to potentially fatal blood clots after one American died and one is in critical condition. Baktari is a pulmonary and critical care expert, vaccine expert, CEO of two medical companies —e7Health.com and US Drug Test Centers.

“It’s interesting. The mRNA vaccine has been around for ten years” -Jonathan Baktari, MD

The trio talked about the Johnson and Johnson vaccine and the importance of the other vaccines. Baktari said the vaccine would be part of the solution to get to herd immunity, so even though it’s currently delayed, it will be an essential piece of the puzzle. The Moderna and Pfizer vaccine use mRNA to introduce the virus, while the J&J vaccine uses the adenovirus.

“It’s interesting. The mRNA vaccine has been around for ten years,” Baktari said. He elaborated that nobody had the guts to use mRNA because folks would have been hesitant to inject genetic material. The pandemic, however, forced us to use the technology.

Vaccines have always been a sensitive subject, as some don’t want to use vaccines. For Baktari, he doesn’t understand the hesitancy. He noted that people are still so willing to use antibiotics and other drugs, but they don’t like it when it comes to vaccines. One of the reasons he thinks is because the government advises it.

–

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

DJ
Dr. José Medina-InojosaCardiovascular disease fellow, Emory University School of Medicine

Dr. José Medina-Inojosa is a cardiovascular disease fellow at Emory University School of Medicine. His earlier work at Mayo Clinic included research on central obesity and cardiovascular risk. In his MarketScale conversations, he returns to practical questions: can a patient reach the clinician, obtain the prescription and understand why a recommendation matters? He co-hosted Health Matters with Alisa Johnsrud in 2021, bringing clinicians into conversations about prevention, health equity and public-health information. His later contributions explore virtual assessments, remote specialist collaboration and the transition to value-based care. In a discussion of body-volume assessment, he put the hoped-for benefit of technology in personal terms: less workload for practitioners and more useful face-to-face interaction with patients.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

The American Hospital Association, West Health and BD will add continuous blood pressure monitoring to surgical care at 10 hospitals, with Vizient measuring results. The pilot tests the workflow around the device: who notices a change, who acts and who hands it off. Whether it spreads depends on cost after startup funding ends.

  • 01A monitor running in two operating rooms can support two different decisions, so device usage counts can say little about whether continuous blood pressure monitoring actually changed surgical care.
  • 02Hospitals evaluating continuous monitoring may already own idle devices; learning why they sit unused, whether training time or an awkward spot in the workflow, points to a different fix than a new purchase order.
  • 03A playbook is expected in roughly a year, aiming to define essential steps while leaving room for smaller or resource-limited hospitals—such as those without 24/7 pharmacy coverage—to adapt workflows locally.

Nov 19, 2026

Four renewal questions that can bring HbA1c closer to the dental chair

Four renewal questions that can bring HbA1c closer to the dental chair

Dr. Deepashree Rajendraprasad, a dentist turned hospital business intelligence developer, gives dental practices four questions for software vendors at contract renewal. They cover HL7 FHIR APIs, health information exchange access, SNODENT terminology and electronic referrals. The standards already exist. The payoff shows up chairside in anticoagulant screening, diabetes-guided periodontal care and bisphosphonate surgical planning.

  • 01Rajendraprasad argues that HbA1c is often already structured in medical systems; getting it to the dental chair starts with what a practice asks its software vendor.
  • 02Two of the five FHIR resources most relevant to dentistry, Patient and Observation, belong to the normative core of FHIR Release 4, where future changes are meant to stay backward compatible.
  • 03At renewal, ask vendors specifics: which FHIR resources they expose, whether they can query the regional HIE, whether they code in SNODENT, and whether they support structured referrals.

Nov 18, 2026

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

A Google Cloud survey found that only 30% of healthcare organizations have scaled advanced or agentic AI across their operations. Johns Hopkins professor Ritu Agarwal emphasizes the need for measured baselines, clinician-led design, and representative data for scaling, noting that pilots often hide key scaling insights.

  • 01A 200-person pilot answers whether a tool works; how it behaves on another hospital's patients and what it costs at full volume mostly show up after the pilot ends.
  • 02Just 30% of healthcare organizations said they’ve scaled advanced or agentic AI across operations, according to a Google Cloud survey of 250+ healthcare executives.
  • 03The sharper pre-pilot question: which disease condition and baseline metric will this tool be judged against?

Nov 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

DJ
Dr. José Medina-Inojosa

Cardiovascular disease fellow

Emory University School of Medicine

Dr. José Medina-Inojosa is a cardiovascular disease fellow at Emory University School of Medicine. His earlier work at Mayo Clinic included research on central obesity and cardiovascular risk. In his MarketScale conversations, he returns to practical questions: can a patient reach the clinician, obtain the prescription and understand why a recommendation matters? He co-hosted Health Matters with Alisa Johnsrud in 2021, bringing clinicians into conversations about prevention, health equity and public-health information. His later contributions explore virtual assessments, remote specialist collaboration and the transition to value-based care. In a discussion of body-volume assessment, he put the hoped-for benefit of technology in personal terms: less workload for practitioners and more useful face-to-face interaction with patients.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512